Remix Therapeutics is a biotechnology company that is developing small molecule therapies for genetic diseases. The company's approach is based on RNA splicing modulation, which involves targeting the splicing process that occurs during gene expression. By modulating RNA splicing, Remix Therapeutics aims to correct genetic mutations that cause diseases such as cystic fibrosis and Duchenne muscular dystrophy. The company was founded in 2020 and is based in Cambridge, Massachusetts.